Gwendolyn Wu

2 weeks ago | biopharmadive.com | Gwendolyn Wu

Prime Medicine will lay off one-quarter of its workforce and deprioritize its clinical-stage program for a rare genetic disease as part of a restructuring announced Monday. Moving forward, Prime will focus on Wilson’s disease and alpha-1 antitrypsin disease, as well as continue work with Cystic Fibrosis Foundation on a treatment for that condition. A collaboration with Bristol Myers Squibb in blood conditions, cancer and immune diseases will also continue.

2 weeks ago | biopharmadive.com | Gwendolyn Wu

AbbVie is staking hundreds of millions of dollars on RNA interference, agreeing on Wednesday to work with biotechnology startup ADARx Pharmaceuticals to develop experimental medicines for neurological conditions, immune diseases and cancer.  Under the , AbbVie will pay ADARx $335 million in cash upfront. The startup could receive “several billion dollars” more in the form of option-related fees and downstream payments, though that money isn’t guaranteed.

2 weeks ago | biopharmadive.com | Gwendolyn Wu

Dive Brief:Novo Nordisk on Wednesday said it will collaborate with biotechnology startup Septerna to hunt new obesity drug prospects, agreeing to pay the California drugmaker more than $200 million in upfront and near-term fees. Septerna and Novo will initially prioritize four experimental programs aimed at drug targets like GLP-1, GIP or glucagon receptors.

1 month ago | biopharmadive.com | Gwendolyn Wu

Biotechnology startups usually turn to a few tried-and-true options to raise the money they need to develop a new drug. Company founders might get initial financial help from friends, family or an angel investor. Perhaps they’ll apply for grant funding or a spot in a startup accelerator. More often than not, they’ll then rely on venture funding to survive. Siren Biotechnology, a San Francisco-based gene therapy startup, has already done some of that work.

1 month ago | finance.yahoo.com | Gwendolyn Wu

Unlock stock picks and a broker-level newsfeed that powers Wall Street. Gwendolyn Wu Thu, May 1, 2025, 2:00 AM 5 min read This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Biotechnology startups usually turn to a few tried-and-true options to raise the money they need to develop a new drug. Company founders might get initial financial help from friends, family or an angel investor.